10-Q: RetinalGenix Q1 2026 Financial Results and Outlook

RetinalGenix Technologies reports a net loss of $590,489 for Q1 2026 while highlighting ongoing liquidity challenges and a going concern warning.

Summary

• Reported a net loss of $590,489 for the three months ended March 31, 2026, compared to a net loss of $587,259 in the same period of 2025.
• Generated zero revenue for the quarter, consistent with the prior year period.
• Total operating expenses were $589,229, primarily driven by research and development costs of $117,064 and general and administrative expenses of $262,149.
• Cash balance as of March 31, 2026, was $180, down from $14,774 at year-end 2025.
• Total liabilities reached $2,563,889, with significant amounts owed to related party Sanovas.
• The company requires approximately $7,000,000 in additional capital to fund product development and operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the extreme liquidity constraints, going concern warning, and material weaknesses in internal controls.

Positives

• Successfully raised $200,000 in May 2026 through the sale of 88,888 shares of common stock.
• Continued progress in the Pearl IRB study for personalized medical evaluations in wet macular degeneration.
• Maintained operational continuity through shared services and infrastructure support from Sanovas.
• General and administrative expenses decreased by 23% year-over-year to $262,149.

Negatives

• Minimal cash position of $180 as of March 31, 2026, raising substantial doubt about the ability to continue as a going concern.
• Accumulated deficit of approximately $18,449,106 as of March 31, 2026.
• Material weakness in internal control over financial reporting due to a lack of segregation of duties.
• Continued reliance on related parties for financing and operational support.

Risks

• Substantial doubt regarding the ability to continue as a going concern due to limited cash and recurring losses.
• Dependence on external financing which may not be available on favorable terms or at all.
• Risks associated with the development and regulatory approval of medical devices and pharmaceutical candidates.
• Potential for future dilution of shareholders if additional equity is issued to raise capital.
• Ineffective internal controls over financial reporting could lead to inaccurate financial disclosures.

Future Outlook

The company plans to launch the RetinalCam in Q4 2026, expand the Pearl IRB study to multistate physicians in late 2026 or early 2027, and continue development of RTG-2023 and RTG-2024. Management anticipates needing $7 million in additional capital to achieve these goals.

Management Comments

• Management acknowledges that the company does not have adequate resources to fund operations beyond June 2026 without additional capital.
• Management is actively working to remediate material weaknesses in internal controls over financial reporting.
• The company intends to pursue additional funding through equity or debt offerings and potential strategic partnerships.

Industry Context

StockSavvy.ai notes that the company operates in the highly capital-intensive ophthalmic R&D sector, where early-stage firms frequently face liquidity crises and reliance on related-party funding while awaiting regulatory milestones.

Comparison to Industry Standards

• The company's reliance on related-party funding is common for micro-cap biotech firms but presents a higher risk profile than industry peers with institutional backing.
• The lack of revenue is standard for pre-commercial R&D stage medical device companies.
• The material weakness in internal controls is a significant deviation from the governance standards expected of larger, more mature public companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Significant expenses are allocated from Sanovas, which is owed $830,632 as of March 31, 2026.
• The company has an exclusive sublicense agreement with Sanovas Ophthalmology for intellectual property.

Stakeholder Impact

• Shareholders face significant dilution risk due to the need for substantial capital raises.
• Creditors and related parties are exposed to the company's liquidity risk.
• Employees and consultants are dependent on the company's ability to secure funding.

Next Steps

• Launch RetinalCam in Q4 2026.
• Expand Pearl IRB study to multistate physicians in winter 2026/early 2027.
• Continue efforts to raise $7 million in additional capital.
• Implement remediation measures for internal control material weaknesses.

Key Dates

Recommendation

The company's extreme lack of liquidity, reliance on related-party debt, and going concern status make it a highly speculative and risky investment, unsuitable for most investors.

Keywords

RetinalGenix, biotech, ophthalmology, medical devices, clinical trials, going concern, 10-Q